Latest study results good on Abiraterone for advanced prostate cancer

From Reuters: J&J drug offers hope in advanced prostate cancer

* Median survival 14.8 months, vs 10.9 months in placebo arm

* Investigator says new drug will change standard of care

* Abiraterone avoids many of side effects of chemotherapy

* J&J to file for regulatory approval by end of year

Full story here: www.reuters.com/assets/print?aid=USLDE69A1MU20101011

Article from Wall St. Journal article: online.wsj.com/article/SB10001424052748703794104575546433109035578.html

Post Edited (proscapt) : 10/11/2010 5:24:56 PM (GMT-6)